Diagonal Therapeutics
PrivateLast Round
Series B
Jan 8, 2026
Total Funding Raised
$253M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Diagonal Therapeutics is a biotechnology company focused on discovering and developing agonist antibodies through a unique platform that integrates proprietary computational and experimental methods to address challenges in drug discovery, ultimately providing therapies for conditions such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diagonal Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Diagonal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 8, 2026 | ||||
| Series A | Apr 3, 2024 |
Diagonal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| Janus Henderson Group | Series B |
| RA Capital Advisors | Series A |
| Balyasny Asset Management L.P. | Series B |
| RA Capital Management | Series A, Series B |
| VF Partners | Series A |
| Deep Track Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2026
Paulina Hill joins the Board of Directors.
- Jan 8, 2026
$125M round raised.
Diagonal Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Diagonal Therapeutics's valuation, stock price, and market status.